We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Arrowhead Pharmaceuticals and Japanese drugmaker Takeda have struck a $1 billion licensing deal to develop a new treatment for alpha-1 antitrypsin-associated liver disease (AATLD). Read More
San Diego-based Allele Biotechnology has filed lawsuits against Regeneron Pharmaceuticals, Pfizer and BioNTech, alleging infringement of its patent for mNeonGreen, a reagent used to develop COVID-19 therapies. Read More
The Institute for Clinical and Economic Review (ICER) has launched a cloud-based, cost-effectiveness modeling program for use by health technology assessment (HTA) agencies when projecting COVID-19 treatment costs. Read More
The NIH’s National Heart, Lung and Blood Institute (NHLBI) has enrolled the first participants in a multicenter phase 2 trial evaluating Rigel Pharmaceuticals’ oral spleen tyrosine kinase inhibitor fostamatinib as a COVID-19 treatment. Read More
Spanish drugmaker Grifols has begun a late-stage trial to evaluate its anti-coronavirus hyperimmune globulin, which is derived from the plasma of recovered COVID-19 patients. Read More
Two FDA expert panels voted in favor of FDA approval for Alkermes’s new drug application (NDA) for its schizophrenia and bipolar disorder investigational drug OLZ/SAM (olanzapine/samidorphan) in a joint session on Friday. Read More
China has officially agreed to support the World Health Organization’s (WHO) COVAX initiative, according to a foreign ministry spokesperson who did not provide the financial details. Read More
Gilead Sciences has released the final results from a late-stage trial of its investigational antiviral remdesivir, which showed that the drug helped patients improve in multiple areas compared to placebo and worked one day faster than previous data showed. Read More